PT141 is being touted as the first true aphrodisiac and the first drug since
the availability of birth control pills 40 years ago that has the potential to
spark another sexual revolution. It is now known by its generic name,
Bremelanotide, which was originally developed from Melanotan II. Melanotan II
was initially tested as a sunless tanning agent and was proven effective for
inducing tanning, but it was also found to cause sexual arousal and spontaneous
erections as unexpected side effects.
PT141 will undergo Phase III clinical studies in the second half of 2006 by
Palatin Technologies, Inc. When the studies are completed, Palatin plans to
submit an NDA to the FDA for approval to market PT141 in the United States in
2007. PT141 belongs to a new class of drugs called melanocortin agonists used to
treat sexual dysfunction. As a result of previous studies, PT141 has proven to
be promising for the treatment of both male and female sexual dysfunction. While
male sexual enhancers such as Viagra, Levitra and Cialis have been on the market
for years, women have been left out in the cold, so to speak, when it comes to
treating sexual dysfunction. Studies on female rats conducted by Palatin
Technologies, the company developing the drug, in conjunction with Concordia
University in Montreal, have found that PT141 reportedly increased sexual
activity in female rats. PT141 was found to encourage the female rats to seek
out males rats for sex. In studies with men, PT141 was shown to improved
erectile dysfunction without the cardiovascular effects found in erectile
dysfunction drugs currently on the market.
Results of the studies were as follows:
Approximately 70% of patients considered PT141 to be as or more
effective than Viagra
The quality of erection with PT141 was perceived to be as good or better
than Viagra in 83% of patients
Safe and effective even at low doses
Faster onset than Viagra and lasts longer than Viagra
PT141 is an odorless, colorless chemical that is administered through a
nasal spray.
Unlike acting directly on the vascular system (blood flow to the penis) like
sexual dysfunction drugs currently available, PT141 (Bremelanotide) acts
directly on the central nervous system. PT141 is a copy of the hormone that
stimulates the melanocyte receptors in the brain that trigger sexual arousal.
PT141 may be effective in treating both the desire as well as the physical
arousal problems of sexual dysfunction. This is what make PT141 a promising and
potentially powerful sexual enhancement drug for both men and
women.
Cord Blodd and
chantex smoking.
PT141 will undergo Phase III clinical studies in the second half of 2006 by
Palatin Technologies, Inc. When the studies are completed, Palatin plans to
submit an NDA to the FDA for approval to market PT141 in the United States in
2007. PT141 belongs to a new class of drugs called melanocortin agonists used to
treat sexual dysfunction. As a result of previous studies, PT141 has proven to
be promising for the treatment of both male and female sexual dysfunction. While
male sexual enhancers such as Viagra, Levitra and Cialis have been on the market
for years, women have been left out in the cold, so to speak, when it comes to
treating sexual dysfunction. Studies on female rats conducted by Palatin
Technologies, the company developing the drug, in conjunction with Concordia
University in Montreal, have found that PT141 reportedly increased sexual
activity in female rats. PT141 was found to encourage the female rats to seek
out males rats for sex. In studies with men, PT141 was shown to improved
erectile dysfunction without the cardiovascular effects found in erectile
dysfunction drugs currently on the market.